The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Sp was over a penny when this was just a possible outcome...now we are here when the news has been great and possible more to come/
to go for me until i get my stake back...roll on a 100% day please..
to show some confidence, rather than PI's find out through other means http://www.commodities-now.com/news/technology/20288-clean-energy-sourcing-selects-brady-to-manage-its-etrm-operations.html
think if news is soon then the sp would be getting closer to the poss 10/11p?
that was meant to say wish....i got out some years ago after doubling my £1k to £2k thinking i had got a good deal!!!!
I will i kept the £1k i had in this from the single figure pence days!!!
AGI Therapeutics (AGI) - Trading below net cash Drug developer AGI Therapeutics is currently valued at £2.6 million, well below its cash pile of $10 million (as at 31st December 2010). The firm concentrates its efforts in the area of specialty indications with unmet medical needs, with particular focus on treatments for conditions which qualify for Orphan Drug status (i.e. those drugs that are applicable for significant competitive advantages such as exclusivity periods, mainly due to the critical nature of the disease). The firm recently identified a promising new lead product candidate, AGI-350, (described as "a novel presentation of an existing marketed drug which AGI will develop to treat a significant unmet medical need in the critical care setting") for which a programme of pre-clinical testing has commenced. "AGI-350 is specifically formulated to allow effective and efficient delivery of the drug directly to the lung to treat a life-threatening, lung-related, condition. There are currently no formulations of the drug available for inhaled delivery, and AGI believes that AGI-350 will represent the first such approved use of the drug to treat the target critical care population." There are currently major changes underway in the pharmaceutical industry, notably the reduction in large pharma R&D budgets, that will see small biotech come under increasing scrutiny, both from the majors and the market in general. Tucking away a few of these might be a very rewarding punt over the next couple of years or so. The cash burn is around $3 million a year so plenty of space for interest to build here.
RNS Number : 4851Z Conygar Investment Company PLC(The) 22 September 2009  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION 22 September 2009 Offer by THE CONYGAR INVESTMENT COMPANY PLC ('CONYGAR' OR 'THE COMPANY') for the whole of the issued and to be issued share capital of THE ADVANTAGE PROPERTY INCOME TRUST LIMITED ('TAP') Cancellation of listing of TAP Shares Conygar announced on 11 September 2009 that it either owned or had received valid acceptances of the Offer in respect of a total of 134,204,958 TAP Shares, representing in aggregate approximately 94.02 per cent. of the current issued share capital of TAP and 91.58 per cent. of the issued share capital of TAP subject to the Offer. Subject to any applicable legal or regulatory requirements, Conygar intends to procure that TAP applies to the FSA for the cancellation of the listing of TAP Shares on the Official List and to the London Stock Exchange for the cancellation of the admission to trading of TAP Shares on the London Stock Exchange's main market for listed securities and to CISX for the cancellation of the listing and admission to trading of TAP shares on CISX. Conygar has today given notice to TAP Shareholders of such applications and it is anticipated that cancellation of TAP's l
Can someone help. With this priced in Euros and the pound getting stronger aganist the EURO will this effect overall profit taken on this once sold and converted back into sterling?
Anyone got any suggestions why this is up today? been here for a while with nothing going on ?
That is a huge buy...anyone got any ideas why and who?
I am pretty new to this...Can anyone tell me if this is good news or not. RNS Number : 2718M Advantage Property Inc Tst (The)Ld 27 January 2009 27 January 2009 The Advantage Property Income Trust Limited ("TAP" or the "Company") Net Asset Value as at 31 December 2008 Net Asset Value The unaudited net asset value per share of The Advantage Property Income Trust Limited ('TAP') as at 31 December 2008 is 56.7 pence. This represents a decline of 19.7 pence per share or 25.8 per cent from the unaudited net asset value per share as at 30 September 2008 of 76.4 pence. The net asset value is calculated under International Financial Reporting Standards ("IFRS"). The net asset value includes all income to 31 December 2008 and is calculated after deduction of all dividends paid prior to that date. It does not include a provision for the dividend for the quarter to 31 December 2008 which is expected to be paid in February 2009. Breakdown of NAV movement Set out below is a breakdown of the change to the unaudited net asset value per share calculated under IFRS over the period from 30 September 2008 to 31 December 2008. Pence per share % of opening NAV Net asset value per share as at 30 76.4 September 2008 Unrealised decrease in valuation of (16.4) (21.5%) property portfolio (including the effect of gearing) Realised loss on sales of properties 0.0 0.0% Decrease in interest rate swap valuation (3.4) (4.5